10-K: ADMA Biologics Reports Fiscal Year 2023 Results, Transitions to Large Accelerated Filer

ADMA Biologics announces its FY2023 financial results, marking its transition to a Large Accelerated Filer and highlighting revenue growth and strategic initiatives.

Summary

• ADMA Biologics reported a net loss of $28.2 million for the year ended December 31, 2023, but achieved adjusted net income of $0.7 million, excluding charges related to debt refinancing and an IT systems disruption.
• The company generated positive cash flow from operations for the first time in its history, driven by revenue growth and acceptance of ASCENIV and BIVIGAM.
• Total revenues for 2023 were $258.2 million, a 68% increase compared to $154.1 million in 2022, primarily due to increased sales of immunoglobulin products.
• The company operates ten FDA-licensed plasma collection facilities and is focused on expanding the commercial production and sales of ASCENIV and BIVIGAM.
• ADMA anticipates revenues of approximately $330 million in 2024 and potentially $380 million in 2025, with gross margins in the range of 40-50% and net income margins in the range of 20-30%.
• These projections translate to potential fiscal year 2024 and 2025 net income of $65 million and $115 million or more and adjusted EBITDA of $90 million and $140 million or more, respectively.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there's significant revenue growth and a transition to a Large Accelerated Filer, the company still faces challenges like net losses and reliance on a few major customers. The positive outlook for 2024 and 2025 is encouraging, but the risks and uncertainties need to be considered.

Positives

• Significant revenue growth driven by increased sales of immunoglobulin products.
• Successful implementation of manufacturing and supply chain enhancements.
• FDA approval for expanded plasma pool production scale for BIVIGAM.
• Expansion of BIVIGAM's label to include pediatric patients.
• Successful initial use of Artificial Intelligence (AI) program, ADMAlytics, to improve efficiencies across our supply chain and production operations.

Negatives

• Net loss of $28.2 million for the year ended December 31, 2023.
• Reliance on a few major customers for a significant portion of revenue.
• Experienced an IT systems disruption in June 2023, resulting in a $2.1 million inventory loss and $0.7 million in plasma center operating expenses.
• The company has a history of losses through December 31, 2023, and may not be able to achieve profitability.

Risks

• The company may need to raise additional capital to operate its business.
• Reliance on third parties for filling, packaging, testing, and labeling of drug substance.
• Estimates of market opportunity and revenue growth may be inaccurate.
• Periodic inspections by the FDA could result in adverse actions.
• Potential for product liability lawsuits.
• Cyberattacks and security breaches could compromise proprietary information.
• Dependence on the safety and availability of plasma supply.
• The market price of the company's common stock may be volatile.

Future Outlook

ADMA anticipates revenues of approximately $330 million in 2024 and potentially $380 million in 2025, with gross margins in the range of 40-50% and net income margins in the range of 20-30%.

Management Comments

• Management believes the Boca Facility has the potential to produce sufficient quantities of immune globulin products representing annual revenues of approximately $330 million in 2024 and potentially $380 million in 2025.
• Management forecasts achieving consolidated gross margins in the range of 40-50% and net income margins in the range of 20-30% at these revenue levels.

Industry Context

The plasma products industry is highly competitive, with ADMA facing competition from both U.S.-based and foreign producers of plasma products.

Comparison to Industry Standards

• The U.S. sales of immune and hyperimmune globulin products for all its uses were reported to be approximately $10.5 billion in 2022 and are expected to exceed $20 billion by 2030.
• ADMA competes with major players like CSL Behring, Grifols, Takeda, and Octapharma.
• The company's manufacturing facility has a peak annual processing capability of up to 600,000 liters.

Related Party Transactions

• The Company leases an office building and equipment from Areth, LLC (Areth) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time , and pays monthly rent on this facility in the amount of $10,000.
• During the years ended December 31, 2023, 2022 and 2021, the Company purchased certain specialized medical equipment and services related to the Companys plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (Genesis) in the amount of $0.4 million, $0.2 million and $0.2 million, respectively.
• On August 15, 2023, two of the Companys executive officers exercised options to purchase 2,909,721 shares of the Companys common stock on a cashless basis, and 688,657 shares of common stock were issued to these executive officers, net of 257,867 shares of common stock to cover a portion of their tax liabilities (see Note 8) .

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and profitability improvements, but also risk of dilution from future capital raises.
• Employees: Continued employment and potential for bonuses and stock options.
• Customers: Continued access to ADMA's products.
• Suppliers: Continued business with ADMA.

Next Steps

• Continue to expand the commercial production of our IG products, as well as the commercial presence, penetration and sales of ASCENIV and BIVIGAM for the treatment of patients with PI.
• Increase marketing efforts around Nabi-HB.
• Expand ASCENIVs FDA-approved uses.
• Improve the Boca Facilitys and ADMA BioCenters operating efficiencies, yields and gross margins.
• Broadly Implement Innovative AI Program, ADMAlytics, to improve efficiencies across our supply chain and production operations.
• Label expansion.
• Expand and develop our pipeline with additional specialty plasma and/or hyperimmune immunoglobulin products.
• Secure new supply contracts for potential contract manufacturing organization (CMO) opportunities.

Key Dates

Keywords

ADMA Biologics, financial results, immunoglobulin, ASCENIV, BIVIGAM, plasma, revenue, profitability, FDA, biologics